Status:
COMPLETED
Development and Evaluation of a Glucagon Sensitivity Test in Individuals With and Without Hepatic Steatosis
Lead Sponsor:
University of Copenhagen
Collaborating Sponsors:
Bispebjerg Hospital
Rigshospitalet, Denmark
Conditions:
Non-Alcoholic Fatty Liver Disease
Glucagon Resistance
Eligibility:
All Genders
25-65 years
Phase:
NA
Brief Summary
Glucagon is secreted from pancreatic alpha-cells in response to protein-rich meals and during hypoglycemia. A physiological feedback system exists between the liver and the pancreatic alpha cells term...
Detailed Description
Amino acids administered orally or intravenously stimulate glucagon secretion from the pancreas and in turn, glucagon is a powerful stimulus for hepatic amino acid turnover through transcriptional (lo...
Eligibility Criteria
Inclusion
- Group 1 (lean controls)
- BMI = 18.6-25 kg/m2
- Male or female
- 25-65 years of age
Exclusion
- Diabetes (ADA criteria)
- Significant alcohol/drug abuse as per investigators judgement
- Amino acid-related diseases such as phenylketonuria
- Kidney disease
- Cardiac problems
- Cancer within the past 1 year
- Severe claustrophobia
- Pacemaker or other non-MR-compatible devices
- Pregnancy or breastfeeding.
- Fib4 score \> 3.25.
- Any medicine, acute illness (within the last two weeks) or other circumstances that in the opinion of the investigator might endanger the participants' safety or compliance with the protocol
- Group 2 (overweight and obese individuals)
- Inclusion Criteria:
- BMI = 25-40 kg/m2
- Male or female
- 25-65 years of age
Key Trial Info
Start Date :
May 27 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 21 2023
Estimated Enrollment :
65 Patients enrolled
Trial Details
Trial ID
NCT04907721
Start Date
May 27 2021
End Date
October 21 2023
Last Update
October 24 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Bispebjerg University Hospital
Copenhagen, Denmark